比较口服奥施康定与美菲康治疗晚期癌症重度疼痛的临床疗效

Comparison of orally administered Kangding and Mei Fei Kang in the treatment of severe pain in advanced cancer

目的比较口服奥施康定与美菲康治疗晚期癌症重度疼痛的临床疗效。方法选取2013年8月～2017年8月本院收治的晚期癌症重度疼痛患者38例作为研究对象,按照随机偶数奇数法分为对照组和实验组,每组19例。对照组选择口服美菲康的方法治疗,实验组选择口服奥施康定的方法治疗,观察比较两组患者的镇痛效果、药物维持剂量与起效时间、治疗前后生活质量以及不良反应发生情况。结果对照组镇痛总有效率与实验组比较差异无统计学意义;实验组起效时间显著短于对照组,差异有统计学意义(P<0.05),两组药物维持剂量比较差异无统计学意义;对照组的不良反应发生率明显高于实验组,差异有统计学意义(P<0.05);治疗后两组食欲、睡眠、日常生活、精神状态、人际交往等生活质量评分均显著优于治疗前,差异有统计学意义(P<0.05),治疗后实验组与对照组间比较差异无统计学意义(P<0.05)。结论奥施康定与美菲康对晚期癌症重度疼痛均具有良好的镇痛效果,可显著改善患者生活质量,但奥施康定具有起效快,安全性高等优势,值得临床优先选择和推广。

Objective To compare the clinical efficacy of Oskonidine and Mefeicam in the treatment of advanced cancer severepain.Methods From August 2013 to August 2017, 38 patients with advanced cancer severe pain were divided into control group （n= 19） and experimental group （n =19）. The patients in the control group were treated with Meficam, and the patients in the experimental group were treated with Oshkangding. The analgesic effect, drug maintenance dose and onset time were observed and compared between the two groups. Quality of life and adverse reactions occurred before and after treatment. Results The total effective rate of analgesia in control group was higher than that in experimental group. There was no significant difference between the two groups, the effective time of the experimental group was significantly shorter than that of the control group （P 〈0.05）, and there was no significant difference in the maintenance dose between the two groups. The incidence of adverse reactions in the control group was significantly higher than that in the experimental group （P〈0.05）, and the scores of appetite, sleep, daily life, mental state and interpersonal communication between the two groups were significantly better than those before treatment. The difference was statistically significant （P〈0.05）, but there was no significant difference between the experimental group and the control group after treatment （P〈0.05）. Conclusion Oshconidine and Maficam have good analgesic effect on severe pain of advanced cancer, and can improve the quality of life of patients. But Oskonidine has the advantages of quick onset and high safety, so it is worth choosing and popularizing in clinic.